AU2020394531B2 - Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 - Google Patents

Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5

Info

Publication number
AU2020394531B2
AU2020394531B2 AU2020394531A AU2020394531A AU2020394531B2 AU 2020394531 B2 AU2020394531 B2 AU 2020394531B2 AU 2020394531 A AU2020394531 A AU 2020394531A AU 2020394531 A AU2020394531 A AU 2020394531A AU 2020394531 B2 AU2020394531 B2 AU 2020394531B2
Authority
AU
Australia
Prior art keywords
pyrazol
acetamide
quinolin
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020394531A
Other languages
English (en)
Other versions
AU2020394531A1 (en
Inventor
Ramón BOSSER ARTAL
Julio Castro Palomino Laria
Begoña PAMPÍN CASAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AgomAb Spain SL
Original Assignee
AgomAb Spain SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AgomAb Spain SL filed Critical AgomAb Spain SL
Publication of AU2020394531A1 publication Critical patent/AU2020394531A1/en
Assigned to Agomab Spain, S.L.U. reassignment Agomab Spain, S.L.U. Amend patent request/document other than specification (104) Assignors: ORIGO BIOPHARMA, S.L.
Application granted granted Critical
Publication of AU2020394531B2 publication Critical patent/AU2020394531B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AU2020394531A 2019-11-28 2020-11-27 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 Active AU2020394531B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19383057.7 2019-11-28
EP19383057 2019-11-28
PCT/EP2020/083566 WO2021105317A1 (en) 2019-11-28 2020-11-27 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Publications (2)

Publication Number Publication Date
AU2020394531A1 AU2020394531A1 (en) 2022-06-09
AU2020394531B2 true AU2020394531B2 (en) 2026-06-25

Family

ID=68808255

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020394531A Active AU2020394531B2 (en) 2019-11-28 2020-11-27 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5

Country Status (15)

Country Link
US (2) US12297186B2 (cg-RX-API-DMAC7.html)
EP (1) EP4065572A1 (cg-RX-API-DMAC7.html)
JP (2) JP7808032B2 (cg-RX-API-DMAC7.html)
CN (1) CN114787145B (cg-RX-API-DMAC7.html)
AR (1) AR120578A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020394531B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022010251A2 (cg-RX-API-DMAC7.html)
CA (1) CA3160963A1 (cg-RX-API-DMAC7.html)
ES (1) ES3029608T1 (cg-RX-API-DMAC7.html)
IL (1) IL293388B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022005843A (cg-RX-API-DMAC7.html)
PH (1) PH12022551177A1 (cg-RX-API-DMAC7.html)
SA (1) SA522432749B1 (cg-RX-API-DMAC7.html)
WO (1) WO2021105317A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202205149B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3978487A1 (en) 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
AU2025225502A1 (en) 2024-02-22 2026-07-30 Agomab Spain S.L.U. Crystalline phase forms of a benzylamide derivative
WO2026082960A1 (en) 2024-10-18 2026-04-23 Agomab Therapeutics Nv 1,5-naphtyridine and quinoline based inhibitors of alk5
WO2026082968A1 (en) 2024-10-18 2026-04-23 Agomab Therapeutics Nv Novel compounds
CN122036718A (zh) * 2026-01-30 2026-05-15 安炎达医药技术(广州)有限公司 一种alk5抑制剂及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066462A1 (en) * 2001-02-02 2002-08-29 Glaxo Group Limited Pyrazole derivatives against tgf overexpression

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3621540A1 (de) 1986-06-27 1988-01-07 Basf Ag Chinolinderivate, verfahren zu ihrer herstellung, diese enthaltende mikrobizide und ihre verwendung zur bekaempfung von bakterien und pilzen
WO2004026306A2 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2004026302A1 (en) * 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CN102056907B (zh) 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2011076725A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
RU2612958C2 (ru) * 2011-07-13 2017-03-14 Ск Кемикалз Ко., Лтд. 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4
US11021468B2 (en) * 2015-04-01 2021-06-01 Rigel Pharmaceuticals, Inc. TGF-ß inhibitors
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
JP2021518855A (ja) 2018-03-02 2021-08-05 ユニヴェルシテ ド ローザンヌ Ｗｎｔシグナル伝達経路阻害剤としてのピラゾール誘導体
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
CN110433164A (zh) * 2019-08-15 2019-11-12 南开大学 TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用
EP3978487A1 (en) 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066462A1 (en) * 2001-02-02 2002-08-29 Glaxo Group Limited Pyrazole derivatives against tgf overexpression

Also Published As

Publication number Publication date
SA522432749B1 (ar) 2025-05-12
US12297186B2 (en) 2025-05-13
JP7808032B2 (ja) 2026-01-28
CN114787145B (zh) 2024-03-26
KR20220107180A (ko) 2022-08-02
WO2021105317A1 (en) 2021-06-03
IL293388B1 (en) 2025-12-01
EP4065572A1 (en) 2022-10-05
ES3029608T1 (en) 2025-06-24
IL293388B2 (en) 2026-04-01
BR112022010251A2 (pt) 2022-09-06
US20250333395A1 (en) 2025-10-30
JP2025163046A (ja) 2025-10-28
AU2020394531A1 (en) 2022-06-09
AR120578A1 (es) 2022-02-23
US20230025933A1 (en) 2023-01-26
JP2023504795A (ja) 2023-02-07
PH12022551177A1 (en) 2024-02-05
ZA202205149B (en) 2025-06-25
MX2022005843A (es) 2022-07-19
IL293388A (en) 2022-07-01
CA3160963A1 (en) 2021-06-03
CN114787145A (zh) 2022-07-22

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: AGOMAB SPAIN, S.L.U.

Free format text: FORMER NAME(S): ORIGO BIOPHARMA, S.L.